Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia

Journal of Clinical Psychiatry

Volumn 64, Issue 6, 2003, Pages 635-639

  Opolka, Jayme L ^a,c   Rascati, Karen L ^b   Brown, Carolyn M ^b   Barner, Jamie C ^b   Johnsrud, Michael T ^b   Gibson, P Joseph ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Eli Lilly and Company ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; COMORBIDITY; CULTURAL ANTHROPOLOGY; DEMOGRAPHY; ETHNOLOGY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE UTILIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES;

EID: 0037929417     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0603     Document Type: Article

References (23)

1. Fabrega H, Mezzich J, Ulrich RF. African-American-white differences in psychopathology in an urban psychiatric population. Compr Psychiatry 1988;29:285-297
2. Lawson WB. Racial and ethnic factors in psychiatric research. Hosp Community Psychiatry 1986;37:50-54
3. Morse JK, Johnson DJ, Heyliger SO. Understanding ethnic disparities in the treatment of affective disorders. Minority Health Today 2000;2:24-27
4. Adebimpe VR. Race, racism, and epidemiological surveys. Hosp Community Psychiatry 1994;45:27-31
5. Jeste DV, Lindamer LA, Evans J, et al. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull 1996;32:243-251
6. Tran PV, Lawson WB, Andersen S, et al. Treatment of the African-American patient with novel antipsychotic agents. In: Herrera JM, Lawson WB, Sramek JJ, eds. Cross Cultural Psychiatry. West Sussex, England: John Wiley & Sons; 1999:131
7. Aponte JF, Rivers RY, Wohl J. Psychological Interventions and Cultural Diversity. Needham Heights, Mass: Allyn & Bacon; 1995:46
8. Lawson WB. Clinical issues in the pharmacotherapy of African-Americans. Psychopharmacol Bull 1996;32:275-281
9. Trierweiler SJ, Neighbors HW, Munday C, et al. Clinician attributions associated with the diagnosis of schizophrenia in African American and non-African American patients. J Consult Clin Psychol 2000;68:171-175
10. Worrel JA, Marken PA, Beckman SE, et al. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000;57:238-258
11. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68
12. Frankenburg FR. Choices in antipsychotic therapy in schizophrenia. Harv Rev Psychiatry 1999;6:241-249
13. Purdon SE, Jones BDW, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000;57:249-258
14. Kendrick T. The newer, "atypical" antipsychotic drugs: their development and current therapeutic use. Br J Gen Pract 1999;49:745-749
15. Foster RH, Goa KL. Olanzapine: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999;15:611-640
16. Foreword. Med Care Res Rev 2000;57(suppl 1):5-10
17. Naylor CD, Guyatt GH, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, 10: how to use an article reporting variations in the outcomes of health services. JAMA 1996;275:554-558
18. SPSS, Inc. SPSS 10.0 for Windows. Chicago Ill: SPSS, Inc; 1999
19. Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 2002;159:567-572
20. Frackiewicz EJ, Sramek JJ, Collazo Y, et al. Risperidone in the treatment of Hispanic schizophrenic patients. In: Herrera JM, Lawson WB, Sramek JJ, eds. Cross Cultural Psychiatry. West Sussex, England: John Wiley & Sons; 1999:183-184
21. Chung H, Mahler JC, Kakuma T. Racial differences in treatment of psychiatric inpatients. Psychiatr Serv 1995;46:586-591
22. Ruiz P, Varner RV, Small DR, et al. Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatr Q 1999;70:163-172
23. Collazo Y, Tam R, Sramek J, et al. Neuroleptic dosing in Hispanic and Asian inpatients with schizophrenia. Mt Sinai J Med 1996;63:310-313